In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is a new treatment for breast cancer.
The FDA recently approved the use of Lynparza (olaparib tablets) to treat patients with metastasized breast cancer and whose tumors have a specific inherited genetic mutation. Lynparza becomes the first PARP inhibitor approved for breast cancer and the first drug for treatment of patients with a BRCA mutation.
According to the National Cancer Institute at the National Institutes of Health, about 20% to 25% of patients with hereditary breast cancers and 5% to 10% of patients with any type of breast cancer have a BRCA gene mutation.
Lynparza blocks an enzyme involved in repairing damaged DNA. By preventing DNA inside BRCA-mutated cancerous cells from being repaired, the drug could slow down or stop tumor growth.
Patients may receive treatment with Lynparza after undergoing the FDA-approved genetic test BRACAnalysis CDx.
Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.